Edahiro, Yoko
Ochiai, Tomonori
Hashimoto, Yoshinori
Morishita, Soji
Shirane, Shuichi
Inano, Tadaaki
Furuya, Chiho
Koike, Michiaki
Noguchi, Masaaki
Usuki, Kensuke
Shiratsuchi, Motoaki
Nakajima, Kei
Ohtsuka, Eiichi
Tanaka, Hiroaki
Kawata, Eri
Nakamae, Mika
Ueda, Yasunori
Aota, Yasuo
Sugita, Yasumasa
Ohara, Shin
Yamasaki, Satoshi
Asagoe, Kohsuke
Yoshida, Shuro
Yamanouchi, Jun
Suzuki, Sayaka
Kondo, Toshinori
Kanisawa, Yuji
Toyama, Kohtaro
Omura, Hiromi
Mizuchi, Daisuke
Sakamaki, Sumio
Ando, Miki
Komatsu, Norio
Article History
Received: 28 January 2023
Revised: 26 March 2023
Accepted: 27 March 2023
First Online: 14 April 2023
Declarations
:
: YE reports grants or contracts from PharmaEssentia Japan K.K., Meiji Seika Pharma and AbbVie G.K.; honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from PharmaEssentia Japan K.K., Takeda Pharmaceutical Co., Ltd. and Novartis Pharma K.K.; and participated on a data safety monitoring board or advisory board of Novartis Pharma K.K. and PharmaEssentia Japan K.K. TO reports grants or contracts from PharmaEssentia Japan K.K. and Meiji Seika Pharma. YH reports honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Takeda Pharmaceutical Co., Ltd. and Novartis Pharma K.K. SJ reports supports for the present manuscript from Otsuka Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Takeda Pharmaceutical Co., Ltd., Novartis Pharma K.K., Sumitomo Pharma Co., Ltd., and Bristol-Myers Squibb K.K.; grants or contracts from FUJIFILM Wako Pure Chemical Corporation, Fuso Pharmaceutical, Pfizer Japan Inc., PharmaEssentia Japan K.K, Shire International GmbH, Perseus Proteomics Inc., Meiji Seika Pharma. SS reports grants or contracts from PharmaEssentia Japan K.K. and Meiji Seika Pharma. KU reports grants or contracts from Amgen-Astellas Biopharma K.K., Otsuka Pharmaceutical Co., LTD., Apellis Pharmaceuticals, Inc., SynBio Pharmaceuticals Ltd., Takeda Pharmaceutical Co., Ltd., Nippon-Shinyaku Co. Ltd., Novartis Pharma K.K., AbbVie G.K., Janssen Pharmaceutical K.K., Bristol-Myers Squibb K.K., Ono Pharmaceutical Co., LTD., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd, MSD K.K., Astellas Pharma Inc., Alexion Pharmaceuticals, Inc., Kyowa Kirin Co., Ltd., Gilead Sciences, Inc., Pfizer Japan Inc., Incyte Biosciences Japan G.K., SynBio Pharmaceuticals Ltd., Celgene K.K., Sumitomo Dainippon Pharma Co., Ltd., Mundipharma K.K., Yakult Honsha Co., and Eisai Co., Ltd.; consulting fees from Alexion Pharmaceuticals, Inc., SynBio Pharmaceuticals Ltd., Nippon-Shinyaku Co. Ltd., Otsuka Pharmaceutical Co., LTD., Chugai Pharmaceutical Co., Ltd., Sanofi K.K., Takeda Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Astellas Pharma Inc., SOBI, and Alnylam Japan; and honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novartis Pharma K.K., Astellas Pharma Inc., Alexion Pharmaceuticals, Inc., Eisai Co., Ltd., MSD, Otsuka Pharmaceutical Co., LTD., Ono Pharmaceutical Co., LTD., Kyowa Kirin Co., Ltd., Celgene K.K., Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Co., Ltd., Nippon-Shinyaku Co. Ltd., PharmaEssentia Japan K.K., Bristol-Myers Squibb K.K., Yakult Honsha Co., Sanofi K.K., Pfizer Japan Inc., AbbVie G.K., and Chugai Pharmaceutical Co., Ltd. MN reports honoraria for lectures from Takeda Pharmaceutical Co., Ltd., Nippon-Shinyaku Co. Ltd., Novartis Pharma K.K. and Bristol-Myers Squibb K.K. YU participated on a data safety monitoring board or advisory board of Sanofi K.K. and Otsuka Pharmaceutical Co., LTD. JY reports honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Takeda Pharmaceutical Co., Ltd. and Chugai Pharmaceutical Co., Ltd. TK reports consulting fees from Sanwa Kagaku Kenkyusyo Co., LTD.; and honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novartis Pharma K.K., Takeda Pharmaceutical CO., LTD., Ono Pharmaceutical Co., LTD., Otsuka Pharmaceutical C0., LTD., Nippon-Shinyaku Co., LTD. and Bristol-Myers Squibb K.K. MA reports grants or contracts from Century Therapeutics and Daiichi Sankyo Co., Ltd; and honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AbbVie G.K., Sumitomo Pharma Co., Ltd., Novartis Pharma K.K. and Sanofi K.K. NK reports grants or contracts from Otsuka Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Sumitomo Pharma Co., Ltd., PharmaEssentia Japan K.K., Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Perseus Proteomics Inc. and Meiji Seika Pharma Co., Ltd.; consulting fees from Japan Tobacco Inc. and PharmaEssentia Japan K.K.; honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novartis Pharma K.K. and Takeda Pharmaceutical Co., Ltd.; and is a board member of PharmaEssentia Japan.